Form 4: Adverum Biotechnologies Director Sells $2.2M in Stock

Adverum Biotechnologies' Director and 10% owner, Braden Michael Leonard, sold over 524,000 shares of common stock for approximately $2.2 million.

Summary

• Braden Michael Leonard, a Director and 10% owner of Adverum Biotechnologies, Inc. (ADVM), reported a sale of common stock.
• On December 4, 2025, Mr. Leonard disposed of 524,560 shares of Adverum Biotechnologies common stock.
• The shares were sold at a price of $4.1947 per share, totaling approximately $2,199,999.99.
• Following the transaction, Mr. Leonard directly beneficially owns 191,800 shares of common stock.
• Additionally, 1,958,080 shares are indirectly beneficially owned through holdings of BML Investment Partners, L.P., where Mr. Leonard is the managing member of the general partner, BML Capital Management, LLC.
• Mr. Leonard disclaims beneficial ownership of the indirectly held shares, except to the extent of his pecuniary interest.

Sentiment

Score: 3

Explanation: The sale of a significant number of shares by a Director and 10% owner is generally perceived as a negative signal by the market, potentially indicating a lack of confidence or a belief that the stock is fully valued.

Negatives

• A Director and 10% owner, Braden Michael Leonard, sold a significant block of 524,560 shares of common stock, valued at approximately $2.2 million, which could be interpreted as a lack of confidence in the company's near-term prospects or current valuation.

Risks

• The sale of a substantial number of shares by a key insider (Director and 10% owner) may signal to the market potential concerns about the company's future performance or valuation, potentially leading to negative investor sentiment and downward pressure on the stock price.

Future Outlook

N/A

Management Comments

• Mr. Leonard disclaims beneficial ownership of shares held by BML Investment Partners, L.P., except to the extent of his pecuniary interest therein.

Industry Context

This insider transaction is specific to Adverum Biotechnologies and does not directly provide broader industry trends. However, insider selling in the biotechnology sector can sometimes reflect individual company-specific developments rather than overall industry sentiment, given the high-risk, high-reward nature of drug development.

Stakeholder Impact

• Shareholders may interpret the insider sale as a negative signal, potentially impacting investor confidence and the company's stock price.

Next Steps

• The reporting person will provide, upon request by the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the transactions at the price sold.

Key Dates

Recommendation

The significant sale of common stock by a Director and 10% owner, Braden Michael Leonard, for approximately $2.2 million, typically signals a lack of confidence in the company's future prospects or current valuation. While individual reasons for selling can vary (e.g., diversification, liquidity needs), a large insider sale from a key stakeholder is generally viewed negatively by the market and could precede further stock price declines. Therefore, a seasoned investor would likely consider selling or reducing their position based on this information.

Keywords

Adverum Biotechnologies, ADVM, Insider Sale, Director Stock Sale, Form 4, Braden Michael Leonard, 10% Owner, Biotechnology, Stock Transaction